Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax or Intensive Chemotherapy for Treatment of Favourable Risk Acute Myeloid Leukaemia
2020-000273-24Phase 2Unknown
- Sponsor
- University of Birmingham
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of venetoclax in acute myeloid leukemia (AML) (2 arms), sponsored by University of Birmingham. Primary endpoint: Molecular event-free survival time (mEFS). Status: unknown.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2020-000273-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000273-24.